On May 29th, the fifth UnionClin Salon closed-door event, co-hosted by the Department of Medical Oncology, Fudan University Shanghai Cancer Center and Shanghai UnionClin Co., Ltd (UnionClin), successfully concluded. This salon brought together influential clinical researchers, pharmaceutical company leaders, industry strategy experts, and investors, focusing on the pain points of new neoplasm drug research and development (R&D). Attendees directly confronted core industry contradictions and engaged in intense intellectual discussions. 

On the occasion of the 35th anniversary of Pudong's development and opening-up, the "Win-Win Pudong, Create the Future" Leading Zone 2025 Conference on Investment Promotion, Business Environment Enhancement, and Development Acceleration was held in Pudong New Area on February 6, 2025. 

Established in 2019, Union Laiya (Shanghai) Data Technology Co., Ltd., a subsidiary of Shanghai UnionClin Co., Ltd., is dedicated to providing comprehensive professional biometric services to domestic and international innovative drug, vaccine, and medical device companies, encompassing clinical trial statistical consultation, trial design and protocol writing, data management, statistical analysis and programming, and more.

On December 11, the "Forum on New Drug/Vaccine Development in the Field of Infectious Diseases" jointly organized by the National Medical Center for Infectious Diseases (Shanghai) (NMCID) and UnionClin, was successfully held in Shanghai. The meeting focused on discussing the collaborative needs throughout the entire process from the laboratory stage to commercialization and aiming to promote exchanges and cooperation among all parties to jointly advance the research and development of innovative drugs in the fields of anti-infection and infectious diseases. 

The golden autumn days come with gleaming sunshine and cool breezes. On October 25, 2024, UnionClin officially relocated its headquarters to the Science Gate of Zhangjiang Science City in Pudong, which means that UnionClin has taken another solid step forward on the path of continuous pursuit of excellence and efficient development.

On October 22, 2024, Shanghai UnionClin Co., Ltd. (hereinafter referred to as UnionClin) was conducting "A Phase 1b/2a Clinical Study of JJH201601 Liposome Injection for the Treatment of Patients with Advanced Pancreatic Cancer, Biliary Tract Cancer, and Hepatocellular Carcinoma" at Nanjing Tianyinshan Hospital, and the first subject was successfully enrolled and treated.